Name:
COVID and Athletes
Description:
COVID and Athletes
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/41f10f6f-1ed9-42a1-8f33-2cd3f0029a24/thumbnails/41f10f6f-1ed9-42a1-8f33-2cd3f0029a24.jpeg?sv=2019-02-02&sr=c&sig=VINd%2BTuwtE8U1vRYHpg0AVwil28lNGBxfcs4fRGlfnA%3D&st=2024-12-21T15%3A42%3A52Z&se=2024-12-21T19%3A47%3A52Z&sp=r
Duration:
T00H02M53S
Embed URL:
https://stream.cadmore.media/player/41f10f6f-1ed9-42a1-8f33-2cd3f0029a24
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/41f10f6f-1ed9-42a1-8f33-2cd3f0029a24/18778976.mp3?sv=2019-02-02&sr=c&sig=PVtoYaIU%2Fug8HXcYAIrxUICoJ%2BxGb8I1okcXQCg7%2FcA%3D&st=2024-12-21T15%3A42%3A52Z&se=2024-12-21T17%3A47%3A52Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's "The Heart Board Review," and other online resources available only through accesscardiology.com. >> Diabetes mellitus can impact treatment of many cardiovascular diseases. What exactly is the effect of diabetes on the risks and benefits of NOACs? [ Music ] Hi. Dr. Bernie here, and welcome to Practice Impact Extra.
The prevalence of diabetes mellitus is increasing both in the United States and worldwide. Diabetes is a common condition associated with atrial fibrillation and it's estimated that there's one in seven patients with atrial fibrillation also have diabetes. It's also recognized that the concomitant atrial fibrillation diabetes increases the risk of stroke and systemic embolic events. A study from the Brigham and Women's Hospital published in the European Heart Journal in October 2020 assessed the benefit/risk balance of NOACs versus warfarin and explored whether there was a modification by diabetes on outcomes between NOACs in patients with and without diabetes mellitus.
They used a meta-analysis of 58,000 patients from four Phase III trials of NOAC versus warfarin in patients with diabetes mellitus, comparing primary outcomes of efficacy and safety. What did they find? NOACs significantly reduced the risk of stroke and systemic emboli in the 18,000 patients with diabetes to a similar degree to 40,500 patients without diabetes. There was no effect of diabetes on the relative reduction of NOACs versus warfarin in reference to major bleeding events.
Cardiovascular deaths were significantly reduced for NOACs in the presence or absence of diabetes mellitus. My assessment and practice impact This data supports the current guideline recommendation for the preferred use of NOACs over warfarin in patients with atrial fibrillation without contraindication and provides reassurance that the efficacy and safety profile of NOACs is not modified by the presence of diabetes mellitus.
Thank you for joining me and see you next time on Practice Impact Extra. >> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to Access Cardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features. To subscribe or learn more, please visit accesscardiology.com.